Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
FREEDOM COVID-19 Anticoagulation Strategy
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Valentin Fuster
- Target Recruit Count
- 3460
- Registration Number
- NCT04512079
- Locations
- 🇨🇴
Centro Médico Imbanaco, Cali, Colombia
🇨🇴Clínica Shaio, Bogotá, Colombia
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 100
- Registration Number
- NCT04462003
- Locations
- 🇪🇬
Faculty of Medicine,Beni-Suef University, Banī Suwayf, Beni-Suef, Egypt
Eliquis Acute Stroke Safety Evaluation
- Conditions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT04435418
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-06-06
- Target Recruit Count
- 700
- Registration Number
- NCT04297150
- Locations
- 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸Hospital Gómez Ulla, Madrid, Spain
🇪🇸Hospital Universitario de La Paz, Madrid, Spain
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 134897
- Registration Number
- NCT04249401
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Science Valley Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT04229264
- Locations
- 🇧🇷
IAMSPE - Sao Paulo Public Servants Hospital, São Paulo, Brazil
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
- Conditions
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 755
- Registration Number
- NCT04218266
- Locations
- 🇫🇷
Hôpital de Rangueil - Toulouse, Toulouse, France
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇸🇪Danderyds sjukhus, Stockholm, Sweden
The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04198844
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 4
- Registration Number
- NCT04191928
- Locations
- 🇺🇸
Thomas Jefferson University Clinical Research Unit, Philadelphia, Pennsylvania, United States
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT04041843
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.